These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33549556)

  • 41. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
    Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
    Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial.
    Neefs J; van den Berg NWE; Krul SPJ; Boekholdt SM; de Groot JR
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):73-80. PubMed ID: 31214914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P;
    Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K
    Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
    Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
    Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
    Myhre PL; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Beldhuis IE; Fleg JL; Lewis E; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2018 Nov; 11(11):e005312. PubMed ID: 30571192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms.
    Vizzardi E; Nodari S; Caretta G; D'Aloia A; Pezzali N; Faden G; Lombardi C; Raddino R; Metra M; Dei Cas L
    Am J Med Sci; 2014 Apr; 347(4):271-6. PubMed ID: 24196866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients.
    Thangaraj SS; Thiesson HC; Svenningsen P; Stubbe J; Palarasah Y; Bistrup C; Jensen BL; Mortensen LA
    Am J Physiol Renal Physiol; 2022 Feb; 322(2):F138-F149. PubMed ID: 34894724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
    Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
    Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
    Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
    J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aldosterone, a new appreciation of its role in heart failure.
    Cha AJ; Malecha SE; Judge KW
    Pharmacotherapy; 2000 Sep; 20(9):1107-15. PubMed ID: 10999504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.